Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibrx Biosciences, Inc. (INBX)

Inhibrx INBRX-106 combo shows 48.3% response rate vs 26.5% in HNSCC Phase 2

Positive Impact 4 of 5 other Written later

Inhibrx Biosciences reported primary endpoint results from the randomized Phase 2 portion of its HexAgon study of INBRX-106 plus pembrolizumab in first-line head and neck squamous cell carcinoma, with a data cutoff of August 19, 2026. The company plans to add about 50 HPV+ oropharyngeal patients to the Phase 2 portion to support a potential accelerated regulatory pathway, then align with the FDA and start a Phase 3 confirmatory portion.

Key points

  • Confirmed objective response rate was 48.3% for INBRX-106 plus pembrolizumab vs 26.5% for pembrolizumab alone; 4 patients (13.8%) in the combination arm had a complete response vs none in the control arm.
  • Median progression-free survival was 9.6 months vs 4.9 months, though the company said median PFS continues to mature.
  • In HPV+ patients, confirmed objective response rate was 80.0% vs 33.3%, based on 10 combination-arm and 9 control-arm patients.
  • The most common treatment-related adverse events were rash, fatigue and diarrhea, which the company described as predominantly low grade.

The filing

CompanyInhibrx Biosciences, Inc. (INBX)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:01 PM ET
Accession number0002007919-26-000047

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.